帕博利珠单抗维持治疗广泛期小细胞肺癌的II期研究
本研究评估铂类联合依托泊苷诱导化疗后疾病控制(缓解或稳定)的广泛期小细胞肺癌患者接受帕博利珠单抗维持治疗的疗效。45例患者入组,中位无进展生存期(PFS)为1.4个月(95%CI:1.3-2.8),1年PFS率13%;中位总生存期(OS)为9.6个月(95%CI:7.0-12),1年OS率37%。结论认为帕博利珠单抗维持治疗相比历史数据未改善中位PFS,但1年PFS率和OS率提示部分患者获益。
要点
- 广泛期小细胞肺癌化疗后维持帕博利珠单抗中位PFS为1.4个月,1年PFS率13%。
- 中位OS为9.6个月,1年OS率37%,提示部分患者可从维持治疗中获益。
- 肿瘤间质界面PD-L1阳性患者中位PFS为6.5个月,阴性者为1.3个月。
核心结论
- 帕博利珠单抗维持治疗相比历史数据未改善中位PFS,但1年PFS率13%和OS率37%提示部分患者获益。
研究设计与样本
- II期研究,纳入45例铂类联合依托泊苷诱导化疗后缓解或稳定的广泛期小细胞肺癌患者。
- 帕博利珠单抗200 mg静脉注射每3周一次,末次化疗后8周内开始。
- 主要终点为自研究注册起的无进展生存期(PFS),总生存期(OS)为关键次要终点。
主要发现
- 45例患者中56%为男性,22%有治疗过的脑转移。
- 中位PFS为1.4个月(95%CI:1.3-2.8),1年PFS率为13%。
- 中位OS为9.6个月(95%CI:7.0-12),1年OS率为37%。
- 30例可评估肿瘤中3例肿瘤细胞PD-L1表达≥1%;20例可评估间质PD-L1。
- 间质界面PD-L1阳性8例中位PFS为6.5个月(95%CI:1.1-12.8),阴性12例为1.3个月(95%CI:0.6-2.5)。
关键数值与推荐
- PD-L1肿瘤细胞阳性定义为表达≥1%。
- 间质界面PD-L1阳性患者中位PFS为6.5个月(95%CI:1.1-12.8),阴性患者为1.3个月(95%CI:0.6-2.5)。
临床怎么用
- 广泛期小细胞肺癌化疗后维持帕博利珠单抗未显示中位PFS获益,但部分患者可能获得长期生存。
- 间质界面PD-L1表达可能作为潜在获益标志物,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to assess the efficacy of maintenance pembrolizumab in patients with extensive-stage SCLC after treatment with platinum and etoposide. METHODS: Patients with extensive-stage SCLC with a response or stable disease after induction chemotherapy were eligible. Pembrolizumab at a dose of 200 mg administered intravenously every 3 weeks was initiated within 8 weeks of the last cycle of chemotherapy. The primary end point of the study was progression-free survival (PFS) from study registration, with overall survival (OS) as a key secondary end point. Available tumor tissue was assessed for expression of programmed death ligand 1 (PD-L1) both in the tumor cells and in the surrounding stroma. Blood for circulating tumor cells was collected before the first, second, and third cycles of pembrolizumab. RESULTS: Of the 45 patients enrolled, 56% were male and 22% had treated brain metastases. The median PFS was 1.4 months (95% confidence interval [CI]: 1.3-2.8), with a 1-year PFS of 13%. The median OS was 9.6 months (95% CI: 7.0-12), with a 1-year OS of 37%. Of the 30 tumors that could be assessed, three had PD-L1 expression (≥1%) in the tumor cells. A total of 20 tumors could be assessed for PD-L1 expression in the stroma. The median PFS in the eight patients with tumors positive for expression of PD-L1 at the stromal interface was 6.5 months (95% CI: 1.1-12.8) compared with 1.3 months (95% CI: 0.6-2.5) in 12 patients with tumors negative for this marker. No unexpected toxicities were observed. CONCLUSION: Maintenance pembrolizumab did not appear to improve median PFS compared with the historical data. However, the 1-year PFS rate of 13% and OS rate of 37% suggest that a subset of patients did benefit from pembrolizumab.
引用
- Gadgeel SM, Pennell NA, Fidler MJ, et al. Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). J Thorac Oncol. 2018. PMID: 29775808. doi:10.1016/j.jtho.2018.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。